Alain Litwin, , MD, MPH, MS
Alain Litwin is vice chair of academics and research at Prisma Health, executive director of the Addiction Research Center at the Health Sciences Center, and professor of medicine at the University of South Carolina School of Medicine–Greenville and the Clemson University School of Health Research. Alain is board certified in internal medicine and addiction medicine, and has been providing medical and addiction care to people who use drugs with complex social, psychiatric and medical needs since 2000. Alain serves on the South Carolina Opioid Emergency Response Team, and co-leads the Prisma Health Opioid Council dedicated to eliminating opioid-related overdoses. As hepatitis C virus (HCV) medical director at Albert Einstein’s Division of Substance Abuse, Alain developed a comprehensive on-site HCV treatment program and peer program to improve medical care of HCV-infected people who use drugs. He expanded patient-centered models of care at numerous community health centers serving thousands of HCV-infected people throughout the Bronx. With funding from NIH, PCORI, CMS, CDC, AHRQ, Robert Wood Johnson Foundation, South Carolina Department of Health and Environmental Control, New York State Department of Health, New York City Department of Health, and industry, Alain’s research has focused on developing and studying models of addiction and medical care for people who inject drugs (PWID), and on increasing access to effective medical care for all people who inject drugs. Alain has worked with government and community organizations on efforts to expand access to both addiction and HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, and task forces with diverse stakeholders. Alain is the principal investigator of the national HERO study and serves on the executive board for the International Network on Hepatitis in Substance Users (INHSU). Alain is a member of the fifth class of Aspen Institute Health Innovators Fellows.